The Ohio Valley Node of the Clinical Trials Network

项目摘要(摘要)： 自2000年成立以来，俄亥俄山谷节点(OVN)一直是NIDA中生产率最高的节点之一 临床试验网络(CTN)节点，领导和参与多站点试验。OVN包括 与四个医疗保健系统、两个药房网络和六个成瘾专业/成功合作 传染病项目。这些合作网站跨越了七个州的区域，其中包括一些州 受阿片类药物(俄亥俄州、肯塔基州和西弗吉尼亚州)和甲基苯丙胺(密苏里州、 肯塔基州和北达科他州)使用。OVN包括中西部、阿巴拉契亚、上南部和原住民 美国代表，这大大加强了CTN的地理和文化多样性。这个 OVN研究核心是OVN的推动力，由温胡森博士领导，他是OVN研究领域的顶尖专家之一 在临床实践环境中进行多点成瘾临床试验。OVN的调查人员有广泛的 药物使用障碍方面的专业知识(温胡森、布朗、伯乐、莱昂斯、蒙哥马利、洛夫沃尔、沃尔什)和 生物信息学(Kaelber，Xu)。OVN研究-实施团队的六名成员带来了&gt；60年的 具有进行CTN临床试验的经验。如果获得资金，我们的总体目标将是利用 在过去19年中获得的经验和专业知识，以进行必要的研究，以满足公众 卫生保健危机，包括阿片类药物使用的流行和兴奋剂使用的惊人增加。为此， 我们将与我们的医疗合作伙伴合作，在不同领域吸引不同的患者和服务系统 在CTN研究中受到物质使用的高度影响。我们还将贡献我们的专业知识来进行 有效性、有效性和实施试验，测试从药物到 针对阿片类药物和兴奋剂使用障碍的行为干预和卫生服务创新。此外， 我们将贡献我们在使用电子健康记录方面的专业知识，用于前瞻性和追溯性 研究研究，包括人工智能在大型医疗保健数据集的应用。总而言之，我们寻求 继续提供科学领导，特别是在可能对临床产生重大影响的研究方面 实践，并与包括治疗提供者在内的各种专业人员有效合作， 来自不同机构的研究人员，以及CTN中心(CCTN)的工作人员，临床协调中心 (C)以及数据和统计中心(DSC)，以支持CTN特派团。

Project Summary (Abstract): Since its establishment in 2000, the Ohio Valley Node (OVN) has been one of the most productive of NIDA's Clinical Trials Network (CTN) nodes, both in leading and participating in multi-site trials. The OVN includes successful partnerships with four healthcare systems, two pharmacy networks, and six addiction specialty/ infectious disease programs. These collaborating sites span a seven-state region including some of the states most heavily impacted by opioid (Ohio, Kentucky, and West Virginia) and methamphetamine (Missouri, Kentucky, and North Dakota) use. The OVN includes Midwestern, Appalachian, Upper South, and Native American representation, which significantly enhances the geographical and cultural diversity of the CTN. The OVN Research Core is the driving force of the OVN and is led by Dr. Winhusen, one of the foremost experts in conducting multi-site addiction clinical trials in clinical practice settings. The OVN investigators have extensive expertise in substance use disorders (Winhusen, Brown, Burlew, Lyons, Montgomery, Lofwall, Walsh) and bioinformatics (Kaelber, Xu). The six members of the OVN research-implementation team bring > 60 years of combined experience conducting CTN clinical trials. If funded, our overall goal would be to utilize the wealth of experience and expertise gained over the past 19 years to conduct the research needed to address public health care crises, including the opioid use epidemic and the alarming increase in stimulant use. To this end, we would work with our healthcare partners to engage a diverse set of patients and service systems in areas highly impacted by substance use in CTN research. We would also contribute our expertise in conducting efficacy, effectiveness, and implementation trials testing the full range of interventions, from medications to behavioral interventions and health service innovations, for both opioid and stimulant use disorders. Moreover, we would contribute our expertise in the use of electronic health records for prospective and retrospective research studies, including the application of artificial intelligence to large healthcare datasets. In sum, we seek to continue providing scientific leadership, particularly on studies that could meaningfully impact clinical practice, and to effectively collaborate with a variety of professionals including treatment providers, investigators from diverse institutions, and staff of the Center for CTN (CCTN), clinical coordinating center (CCC) and data and statistics center (DSC) in support of the CTN mission.